Marblegate Q2 Loss Narrows to $4.8M, But Cash Drops to $7.3M and Warrants Face OTCQX Removal
MGTE is trading near its 52-week low of $0.92 (9.7% above the low) on light trading volume (0.3× avg).
Summary
Marblegate Capital reported a much smaller Q2 loss of $4.8M, but cash dropped to $7.3M and its warrants face removal from OTCQX unless the bid price recovers by October 6.
Key Events · Earnings and Guidance · MGTE
-
Q2 Loss Narrows to $4.8M
Net loss attributable to common stockholders was $4.3M for Q2 2026, down from $48.0M in Q2 2025, driven by a $49.8M swing in income tax expense.
-
Cash Position Drops 71%
Cash and cash equivalents fell to $7.3M at June 30, 2026 from $25.3M at year-end 2025, with operating activities using $12.0M in the first half.
-
Credit Facility Draw Increased
The company drew an additional $10M on April 15, 2026, bringing total outstanding advances under the DZ Bank credit facility to $35M, with $20.2M of additional borrowing capacity remaining.
-
Warrants Face OTCQX Removal
OTC Markets issued a deficiency notice on July 8, 2026 because warrant bid price closed below $0.10 for 30 consecutive days. The cure period expires October 6, 2026.
Analysis · MGTE · Finance
Marblegate's Q2 loss narrowed dramatically from $47.3M to $4.8M, but the balance sheet tells a tighter story: cash fell from $25.3M to $7.3M in six months. The company drew another $10M on its credit facility in April, and its warrants received a deficiency notice from OTC Markets on July 8 with a cure deadline of October 6. If the warrants are removed from OTCQX, liquidity could suffer and the stock may be classified as a penny stock, further limiting trading.
At the time of this filing, MGTE was trading at $1.01 on OTC in the Finance sector, with a market capitalization of approximately $74.7M. The 52-week trading range was $0.92 to $2.54. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.